Insmed (INSM) EBITDA (2010 - 2026)

Insmed's EBITDA history runs 17 years deep, the most recent figure standing at -$165.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 35.34% year-over-year to -$165.0 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 16.82% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.08% from the prior year.
• EBITDA was -$165.0 million for Q1 2026 at Insmed, up from -$329.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$95.8 million in Q1 2022 to a low of -$369.8 million in Q3 2025.
• Historically, EBITDA has averaged -$211.0 million across 5 years, with a median of -$184.7 million in 2023.
• The sharpest annual moves came in 2023 and 2026: EBITDA plunged 156.52% in 2023, then soared 35.34% in 2026.
• A 5-year view of EBITDA shows it stood at -$158.0 million in 2022, then declined by 16.93% to -$184.7 million in 2023, then declined by 29.05% to -$238.4 million in 2024, then sank by 38.02% to -$329.0 million in 2025, then jumped by 49.85% to -$165.0 million in 2026.
• The last three EBITDA figures came in at -$165.0 million (Q1 2026), -$329.0 million (Q4 2025), and -$369.8 million (Q3 2025), per Business Quant data.